Clinical Trial Update: Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing safety and effect on central retinal thickness of BI 1026706 in patients with diabetic macular edema; completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Macular Edema

Drugs mentioned

• BI 1026706 (BI 1026706)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Macular Edema | Phase 2 | Status: COMPLETED | Results posted: 2019-03-20